Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
